Eisai R&d Management Co., Ltd.

Takayuki Nakagawa

Tomohiro Matsushima

Yuji Yamamoto

Hiroshi Obaishi

Yasuhiro Funahashi

Akihiko Tsuruoka

Saori Miyano

The present application discloses a therapeutic agent for breast cancer, comprising 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof.

Therapeutic agent for breast cancer

An antitumor agent for combined use of a compound or pharmaceutically acceptable salt thereof represented by Formula (I) and a compound or pharmaceutically acceptable salt thereof represented by Formula (II) exhibits an excellent antitumor effect compared to cases where these are individually used, and exhibits antitumor effects against various cancer types: wherein Ris azetidinyl and the like, Rto Ris a hydrogen atom or a halogen atom, Ris Ccycloalkyl and the like, Ris a hydrogen atom and the like, and Ris a halogen atom and the like.

Antitumor agent using compounds having kinase inhibitory effect in combination

The present invention relates to a therapeutic agent represented by the General formula (I), or a pharmacologically acceptable salt thereof, or a solvate of the compound or the salt thereof:  The therapeutic agent comprises a substance having the activity of inhibiting kinase activity of fibroblast growth factor receptor 2 ('FGFR2'). The therapeutic agent can be used for treating undifferentiated gastric cancer, and can also be used to treat organisms comprising a cell overexpressing FGFR2 or a cell expressing mutant FGFR2, or both. The present invention further relates to a pharmaceutical composition comprising an FGFR2 inhibitory and methods of treatment therewith. The present invention also relates to a method for predicting the effect of an FGFR2 inhibitory substance on a patient.

Antitumor agent for undifferentiated gastric cancer

A method of treating esophageal cancer, containing the step of administering to a patient suffering from esophageal cancer, a compound or a salt thereof, wherein the compound is: N-(2-fluoro-4-{[2-({[4-(4-methylpiperazin-1-yl)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N-[4-({2-[(azetidin-1-ylcarbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N&#x2032;-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N-{2,5-difluoro-4-[(2-{[(3-hydroxyazetidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]phenyl}-N&#x2032;-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N-(2,5-difluoro-4-{[2-({[4-(4-methylpiperazin-1-yl)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N&#x2032;-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N-(2,5-difluoro-4-{[2-({[methyl(1-methyl-piperidin-4-yl)amino]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N&#x2032;-(4-fluorophenyl)-cyclopropane-1,1-dicarboxamide, or N-(2,5-difluoro-4-{[2-({[3-(hydroxymethyl)azetidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N&#x2032;-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.

Growing community of inventors

Tsukuba, Japan

Takayuki Nakagawa